Bölüm notları
Preston Hayes and Logan Pierce talk through the base, bear, and bull cases for Definium Therapeutics stock ahead of its Q3 earnings on Monday, November 9, its three positive Phase 3 readouts for DT120, the FDA pre-NDA meeting, and what to listen for on the call, plus what to watch next.
Web sitesi: podcasters.spotify.com

